Literature DB >> 27575022

Regulation of cardiac hypertrophy and remodeling through the dual-specificity MAPK phosphatases (DUSPs).

Ruijie Liu1, Jeffery D Molkentin2.   

Abstract

Mitogen-activated protein kinases (MAPKs) play a critical role in regulating cardiac hypertrophy and remodeling in response to increased workload or pathological insults. The spatiotemporal activities and inactivation of MAPKs are tightly controlled by a family of dual-specificity MAPK phosphatases (DUSPs). Over the past 2 decades, we and others have determined the critical role for selected DUSP family members in controlling MAPK activity in the heart and the ensuing effects on ventricular growth and remodeling. More specifically, studies from mice deficient for individual Dusp genes as well as heart-specific inducible transgene-mediated overexpression have implicated select DUSPs as essential signaling effectors in the heart that function by dynamically regulating the level, subcellular and temporal activities of the extracellular signal-regulated kinases (ERKs), c-Jun N-terminal kinases (JNKs) and p38 MAPKs. This review summarizes recent literature on the physiological and pathological roles of MAPK-specific DUSPs in regulating MAPK signaling in the heart and the effect on cardiac growth and remodeling.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cardiac hypertrophy; Concentric remodeling; Dual specificity phosphatases; Mitogen-activated protein kinases

Mesh:

Substances:

Year:  2016        PMID: 27575022      PMCID: PMC5154921          DOI: 10.1016/j.yjmcc.2016.08.018

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  92 in total

Review 1.  Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale.

Authors:  Beth A Rose; Thomas Force; Yibin Wang
Journal:  Physiol Rev       Date:  2010-10       Impact factor: 37.312

2.  Inactivation of JNK activity by mitogen-activated protein kinase phosphatase-2 in EAhy926 endothelial cells is dependent upon agonist-specific JNK translocation to the nucleus.

Authors:  C J Robinson; C M Sloss; R Plevin
Journal:  Cell Signal       Date:  2001-01       Impact factor: 4.315

3.  DUSP10 regulates intestinal epithelial cell growth and colorectal tumorigenesis.

Authors:  C W Png; M Weerasooriya; J Guo; S J James; H M Poh; M Osato; R A Flavell; C Dong; H Yang; Y Zhang
Journal:  Oncogene       Date:  2015-03-16       Impact factor: 9.867

Review 4.  Diversity and specificity of the mitogen-activated protein kinase phosphatase-1 functions.

Authors:  Ahmed Lawan; Hao Shi; Florian Gatzke; Anton M Bennett
Journal:  Cell Mol Life Sci       Date:  2012-06-14       Impact factor: 9.261

Review 5.  Genetic and epigenetic control of metabolic health.

Authors:  Robert Wolfgang Schwenk; Heike Vogel; Annette Schürmann
Journal:  Mol Metab       Date:  2013-09-25       Impact factor: 7.422

6.  p38alpha mitogen-activated protein kinase plays a critical role in cardiomyocyte survival but not in cardiac hypertrophic growth in response to pressure overload.

Authors:  Kazuhiko Nishida; Osamu Yamaguchi; Shinichi Hirotani; Shungo Hikoso; Yoshiharu Higuchi; Tetsuya Watanabe; Toshihiro Takeda; Soh Osuka; Takashi Morita; Gen Kondoh; Yoshihiro Uno; Kazunori Kashiwase; Masayuki Taniike; Atsuko Nakai; Yasushi Matsumura; Jun-ichi Miyazaki; Tatsuhiko Sudo; Kenichi Hongo; Yoichiro Kusakari; Satoshi Kurihara; Kenneth R Chien; Junji Takeda; Masatsugu Hori; Kinya Otsu
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

7.  Dual specificity phosphatase 4 mediates cardiomyopathy caused by lamin A/C (LMNA) gene mutation.

Authors:  Jason C Choi; Wei Wu; Antoine Muchir; Shinichi Iwata; Shunichi Homma; Howard J Worman
Journal:  J Biol Chem       Date:  2012-10-09       Impact factor: 5.157

8.  Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling.

Authors:  Julian C Braz; Orlando F Bueno; Qiangrong Liang; Benjamin J Wilkins; Yan-Shan Dai; Stephanie Parsons; Joseph Braunwart; Betty J Glascock; Raisa Klevitsky; Thomas F Kimball; Timothy E Hewett; Jeffery D Molkentin
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

9.  Targeted inhibition of p38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia-reperfusion in vivo.

Authors:  Robert A Kaiser; Orlando F Bueno; Daniel J Lips; Pieter A Doevendans; Fred Jones; Thomas F Kimball; Jeffery D Molkentin
Journal:  J Biol Chem       Date:  2004-01-28       Impact factor: 5.157

10.  DUSPs, to MAP kinases and beyond.

Authors:  Ching-Yu Huang; Tse-Hua Tan
Journal:  Cell Biosci       Date:  2012-07-09       Impact factor: 7.133

View more
  32 in total

1.  Cardiac resynchronization therapy reduces expression of inflammation-promoting genes related to interleukin-1β in heart failure.

Authors:  Kenneth Bilchick; Hema Kothari; Aditya Narayan; James Garmey; Abdullah Omar; Brian Capaldo; Coleen McNamara
Journal:  Cardiovasc Res       Date:  2020-06-01       Impact factor: 10.787

2.  C33(S), a novel PDE9A inhibitor, protects against rat cardiac hypertrophy through upregulating cGMP signaling.

Authors:  Pan-Xia Wang; Zhuo-Ming Li; Si-Dong Cai; Jing-Yan Li; Ping He; Yi Huang; Guo-Shuai Feng; Hai-Bin Luo; Shao-Rui Chen; Pei-Qing Liu
Journal:  Acta Pharmacol Sin       Date:  2017-06-26       Impact factor: 6.150

3.  Protein tyrosine phosphatase 1B regulates miR-208b-argonaute 2 association and thyroid hormone responsiveness in cardiac hypertrophy.

Authors:  Gérald Coulis; Avinash D Londhe; R Sudheer Sagabala; Yanfen Shi; David P Labbé; Alexandre Bergeron; Pramod Sahadevan; Sherin A Nawaito; Fatiha Sahmi; Marie Josse; Valérie Vinette; Marie-Claude Guertin; Gérard Karsenty; Michel L Tremblay; Jean-Claude Tardif; Bruce G Allen; Benoit Boivin
Journal:  Sci Signal       Date:  2022-04-19       Impact factor: 9.517

4.  Cardiomyocyte-specific deletion of GSK-3β leads to cardiac dysfunction in a diet induced obesity model.

Authors:  Manisha Gupte; Samvruta Tumuluru; Jennifer Y Sui; Anand Prakash Singh; Prachi Umbarkar; Shan S Parikh; Firdos Ahmad; Qinkun Zhang; Thomas Force; Hind Lal
Journal:  Int J Cardiol       Date:  2018-02-03       Impact factor: 4.164

5.  Mitochondrial ROS Drive Sudden Cardiac Death and Chronic Proteome Remodeling in Heart Failure.

Authors:  Swati Dey; Deeptankar DeMazumder; Agnieszka Sidor; D Brian Foster; Brian O'Rourke
Journal:  Circ Res       Date:  2018-06-13       Impact factor: 17.367

6.  Microfibrillar-Associated Protein 4 Regulates Stress-Induced Cardiac Remodeling.

Authors:  Lisa E Dorn; William Lawrence; Jennifer M Petrosino; Xianyao Xu; Thomas J Hund; Bryan A Whitson; Matthew S Stratton; Paul M L Janssen; Peter J Mohler; Anders Schlosser; Grith L Sorensen; Federica Accornero
Journal:  Circ Res       Date:  2021-02-03       Impact factor: 17.367

7.  Andrographolide Protects against Aortic Banding-Induced Experimental Cardiac Hypertrophy by Inhibiting MAPKs Signaling.

Authors:  Qing Q Wu; Jian Ni; Ning Zhang; Hai H Liao; Qi Z Tang; Wei Deng
Journal:  Front Pharmacol       Date:  2017-11-14       Impact factor: 5.810

8.  Dual-specificity Phosphatase 9 protects against Cardiac Hypertrophy by targeting ASK1.

Authors:  Lang Jiang; Lingyun Ren; Xin Guo; Jing Zhao; Hao Zhang; Shanshan Chen; Sheng Le; Hao Liu; Ping Ye; Manhua Chen; Jiahong Xia
Journal:  Int J Biol Sci       Date:  2021-05-27       Impact factor: 6.580

9.  Identifying the key regulators that promote cell-cycle activity in the hearts of early neonatal pigs after myocardial injury.

Authors:  Eric Zhang; Thanh Nguyen; Meng Zhao; Son Do Hai Dang; Jake Y Chen; Weihua Bian; Gregory P Walcott
Journal:  PLoS One       Date:  2020-07-30       Impact factor: 3.240

10.  Interactions between the ERK1/2 signaling pathway and PCAF play a key role in PE‑induced cardiomyocyte hypertrophy.

Authors:  Qian Mao; Shuqi Wu; Chang Peng; Bohui Peng; Xiaomei Luo; Lixin Huang; Huanting Zhang
Journal:  Mol Med Rep       Date:  2021-07-19       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.